Genzyme beats Street

GENZ reported third quarter 2005 non-GAAP EPS of $0.61, beating the Street estimate by $0.03 and up 24% from $0.49 in the third quarter of 2004. Third quarter revenues increased 24% to $708.1 million from $569.2 million in the same quarter last year.

Third quarter sales of Cerezyme imiglucerase for Type I Gaucher's disease were $238.3 million, up 14% from $208.4 million in prior year's quarter. Sales of Renagel sevelamer for end-stage renal disease (ESRD) were $106.9 million, up 15% from $93.3 million last year. Fabrazyme agalsidase beta for Fabry's disease posted second quarter sales of $79.1 million, up 36% from $58 million a year ago. ...